Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTFB.L Share News (MTFB)

  • There is currently no data for MTFB

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Amphion Innovations To Work With Debt Providers To Refinance Facility

Wed, 12th Jun 2019 18:16

(Alliance News) - Amphion Innovations PLC said Wednesday its debt providers have told the company the excess value of the collateral does not meet the terms of an agreed facility between the pair.

Shares in the company closed down 27% at 0.20 pence each.

In March, Amphion amended its loan facility it first agreed in 2014 but then amended last October. Then in April, the company pledged its holding in Polarean Imaging PLC as additional security against its loan facility with its debt provider.

As part of the amendment in March, Amphion pledged 18.0 million shares in partner company Motif Bio PLC shares to act as security for the loan. The amendment in April saw the loan also be secured by the company's 18.4 million shares in Polarean.

As of Tuesday, the loan balance outstanding is about USD3.2 million, with 10.9 million Motif Bio shares held.

Shares in Motif Bio closed down 8.2% Wednesday at 3.49 pence.

"The board is working closely with the lender regarding potential resolution in connection with the collateral requirement and further announcements will be made as appropriate," the company said.

Amphion added: "The company remains highly cash constrained and continues to consider both its short term and medium term funding options and work with the company's note holders. The outstanding facility balance plus accrued interest are currently due for repayment on September 30."

Amphion retains its beneficial interest in all pledged shares, although it has transferred the legal title to the majority of these.

More News
24 Oct 2019 10:31

UK WINNERS & LOSERS SUMMARY: Woodford Trust Up 30% As Schroders Tapped

UK WINNERS & LOSERS SUMMARY: Woodford Trust Up 30% As Schroders Tapped

Read more
10 Oct 2019 11:52

Motif Bio Meeting With US FDA Confirms Need For Another iclaprim Trial

Motif Bio Meeting With US FDA Confirms Need For Another iclaprim Trial

Read more
2 Oct 2019 11:59

Motif Bio To Raise GBP600,000 Via Placing To Fund Major Restructure

Motif Bio To Raise GBP600,000 Via Placing To Fund Major Restructure

Read more
1 Oct 2019 17:09

Motif Bio To Become Cash Shell If Restructuring Proposals Accepted

Motif Bio To Become Cash Shell If Restructuring Proposals Accepted

Read more
2 Sep 2019 11:39

Motif Bio Delays Next Amortisation Date Of Hercules Loan Facility

(Alliance News) - Novel antibiotics-focused biopharmaceutical company Motif Bio PLC said Monday it has agreed with Hercules Capital Inc to postpone the next amortisation date for its loan and date

Read more
19 Aug 2019 10:46

WINNERS & LOSERS SUMMARY: IXICO Rises On Positive Outlook

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - WINNERS----------J up 3.8%. The is

Read more
19 Aug 2019 09:29

Motif Bio Receives US State Funding For Iclaprim Listeria Study

(Alliance News) - Biopharmaceutical firm Motif Bio PLC said Monday that the US government will fund a study on the effectiveness of the iclaprim drug against listeria monocytogenes.Shares a

Read more
1 Aug 2019 11:43

Motif Bio Postpones Next Amortisation Date Of Hercules Loan Facility

(Alliance News) - Biopharmaceutical firm Motif Bio PLC said on Thursday has amended its loan agreement with Hercules Capital Inc, delaying the next amortisation date by one month to September a to

Read more
6 Jun 2019 10:47

WINNERS & LOSERS SUMMARY: Rolls Royce And L&G Rise On Pension Pact

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Thursday.----------FTSE 100 - WINNERS----------Rolls up

Read more
31 May 2019 15:32

Motif Bio Shareholders Reject Remuneration Report Resolution

LONDON (Alliance News) - Motif Bio PLC on Friday said that shareholders voted against approval of the company's remuneration report.At the clinical-stage biopharmaceutical firm's on

Read more
1 May 2019 10:46

Motif Bio to work with Lamellar on cystic fibrosis treatment possibility

(Sharecast News) - Clinical-stage biopharmaceutical company Motif Bio has signed an agreement with Lamellar Biomedical, under which Motif Bio would conduct an in vivo preclinical study evaluating iclaprim in combination with Lamellar's patented 'Lamellasome' technology.

Read more
1 May 2019 09:26

Motif Bio Shares Up On Agreement With Lamellar To Start Clinical Study

LONDON (Alliance News) - Shares rose in Motif Bio PLC on Wednesday as it signed an agreement with Lamellar Biomedical to study the combination of Motif's iclaprim with Lamellar's in the at

Read more
26 Apr 2019 14:09

Motif Bio Appoints Andrew Powell As Non-Executive Director

LONDON (Alliance News) - Motif Bio PLC, a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, said Friday it has appointed Andrew Powell as non-executive has as

Read more
15 Apr 2019 10:50

Motif Bio 2018 Loss Narrows As Research Costs Fall Despite US Delay

LONDON (Alliance News) - Motif Bio PLC said Monday its 2018 loss narrowed significantly as research costs fell, despite an unexpected delay in its new drug application in the US.In 2018, to

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.